posted on 2013-02-20, 00:42authored byMichelle L. Scalley-Kim, Bruce W. Hess, Ryan L. Kelly, Anne-Rachel F. Krostag, Kurt H. Lustig, John S. Marken, Pamela J. Ovendale, Aaron R. Posey, Pamela J. Smolak, Janelle D. L. Taylor, C. L. Wood, David L. Bienvenue, Peter Probst, Ruth A. Salmon, Daniel S. Allison, Teresa M. Foy, Carol J. Raport
Inhibition of chemotaxis of (A) CCR5 transfectants to a pool of recombinant CCL3, CCL4, and CCL5 and (B) CCR1 transfectants to a pool of CCL3 and CCL5, by MAb d5d7 antibody, vCCI-Fc, individual commercial anti-chemokine antibodies (anti-CCL3, anti-CCL4, and anti-CCL5), and IgG controls. Chosen chemokine concentrations were those that produced 50% maximal chemotaxis when tested individually (a pool of 3 ng/mL CCL3, 10 ng/mL CCL4, and 3 ng/mL CCL5 was used in CCR5 experiments and a mixture of 20 ng/mL CCL3 and 5 ng/mL CCL5 was used in CCR1 experiments).